Bicycle Therapeutics (BCYC) Stock Price, News & Analysis

Company Overview

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners. Its oncology portfolio includes targeted agents aimed at tumor-associated receptors and tumor-penetrating ligands designed to deliver therapeutic payloads. In parallel, the company is advancing candidates in neuroscience and immuno-oncology, seeking to address high-unmet-need conditions. Bicycle’s programs are being evaluated in preclinical and early clinical studies, and the company has established research collaborations with several global biopharmaceutical organizations to accelerate the clinical development of its lead molecules.

Headquartered in Cambridge, UK, Bicycle Therapeutics has expanded its presence with operations in the United States to support its growing clinical activities and partnerships. The company is led by an experienced management team with deep expertise in peptide chemistry, translational research and drug development. By integrating its proprietary platform with strategic alliances, Bicycle Therapeutics aims to advance a new class of precision medicines capable of reaching challenging therapeutic targets with improved safety and efficacy profiles.

Key Stats

• Today's Range: $7.80 to $8.20
• 50-Day Range: $6.86 to $8.53
• 52-Week Range: $6.10 to $28.67
• Volume: 272,903 shs
• Average Volume: 303,408 shs
• Market Capitalization: $554.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.22
• Consensus Rating: Moderate Buy

Bicycle Therapeutics Stock Analysis - MarketRank™

Bicycle Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 263rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bicycle Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Bicycle Therapeutics has a consensus price target of $22.22, representing about 177.8% upside from its current price of $8.00.

Amount of Analyst Coverage

Bicycle Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($3.06) to ($3.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bicycle Therapeutics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bicycle Therapeutics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bicycle Therapeutics has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.11% of the outstanding shares of Bicycle Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Bicycle Therapeutics has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Bicycle Therapeutics has recently decreased by 8.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bicycle Therapeutics does not currently pay a dividend.

Dividend Growth

Bicycle Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.11% of the outstanding shares of Bicycle Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Bicycle Therapeutics has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Bicycle Therapeutics has recently decreased by 8.18%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.04

News Sentiment

Bicycle Therapeutics has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Bicycle Therapeutics this week, compared to 5 articles on an average week.

MarketBeat Follows

3 people have added Bicycle Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $71,738.00 in company stock.

Percentage Held by Insiders

Only 8.50% of the stock of Bicycle Therapeutics is held by insiders.

Percentage Held by Institutions

86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BCYC Stock Analysis - Frequently Asked Questions

How have BCYC shares performed this year?

Bicycle Therapeutics' stock was trading at $14.00 at the beginning of 2025. Since then, BCYC stock has decreased by 42.9% and is now trading at $8.00.

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) released its earnings results on Friday, August, 8th. The company reported ($1.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.95) by $0.19. The company earned $2.90 million during the quarter, compared to the consensus estimate of $9.43 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 32.43% and a negative net margin of 1,257.00%.

When did Bicycle Therapeutics IPO?

Bicycle Therapeutics (BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bicycle Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bicycle Therapeutics investors own include Vale (VALE), uniQure (QURE), Clean Energy Fuels (CLNE), Paycom Software (PAYC), Grayscale Ethereum Trust (ETH) (ETHE), Curaleaf (CURLF) and Marathon Oil (MRO).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 10/07/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCYC
• CIK: 1761612
• Web: www.bicycletherapeutics.com
• Phone: 441223261503
• Fax: N/A
• Employees: 240
• Year Founded: 2009

Price Target and Rating

• Average Price Target for Bicycle Therapeutics: $22.22
• High Price Target: $44.00
• Low Price Target: $10.00
• Potential Upside/Downside: +177.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$169.03 million
• Net Margins: -1,257.00%
• Pretax Margin: -1,287.33%
• Return on Equity: -32.43%
• Return on Assets: -26.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.39
• Quick Ratio: 10.39

Sales & Book Value

• Annual Sales: $19.28 million
• Price / Sales: 28.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.48 per share
• Price / Book: 0.70

Miscellaneous

• Outstanding Shares: 69,307,000
• Free Float: 63,416,000
• Market Cap: $554.46 million
• Optionable: Optionable
• Beta: 1.47